Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects

Cancer Cell International

Xiao-Xu Liu²  Meng Wang²  Wei-Li Min²  Hong-Tao Ren²  Yang Zhao²  Shuai Lin²  Yong-Ping Shao¹  Xi-Jing Wang²  Hua-Feng Kang²  Zhi-Jun Dai¹ 

[1] Center for Translational Medicine, Frontier Institute of Science and Technology (FIST), Xi’an Jiaotong University, Xi’an 710049, China;Department of Oncology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

关键词: Meta-analysis;    Susceptibility;    Polymorphism;    Breast cancer;    AURKA;   

Others  :  1121663
DOI  :  10.1186/s12935-014-0091-y

 received in 2014-06-25, accepted in 2014-09-01,  发布年份 2014

【 摘 要 】

Background

Published data on the association between AURKA polymorphisms and breast cancer (BC) risk are inconclusive. This meta-analysis was performed to derive a more precise estimation on the relationship between AURKA polymorphisms (rs2273535 and rs1047972) and BC risk.

Methods

PubMed, Web of Knowledge and Embase were searched for relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to estimate the strength of associations. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were performed for allele contrast genetic model, homozygous genetic model, heterozygote genetic model, dominant model, and recessive model, respectively.

Results

A total of 13 studies (16,349 BC patients and 20,872 case-free controls) were involved in this meta-analysis. Meta-analysis showed that there was significant association between rs2273535 and BC risk in three genetic models in the overall population (A vs. T: OR = 1.08, 95% CI = 1.01–1.15, P = 0.02; AA vs. TT: OR = 1.36, 95% CI = 1.06-1.73, P < 0.00001; AA vs. TT + TA: OR = 1.15, 95% CI = 1.01-1.31, P = 0.04). In the subgroup analysis by ethnicity, the effects remained in Asians (allele contrast genetic model: OR = 1.12, 95% CI = 1.00-1.26, P = 0.04 and homozygote comparison: OR = 1.22, 95% CI = 1.06-1.41, P = 0.007). However, no genetic models reached statistical association in Cauasians. Rs1047972 polymorphism was associated with BC risk in the overall population based on homozygote comparison (AA vs. GG: OR = 0.81, 95% CI = 0.66-0.99, P = 0.04). When stratified by ethnicity, rs1047972 polymorphism had a decreased association with BC risk in Caucasians based on allele contrast genetic model, homozygote comparison, the dominant model and the recessive model. However, there was no association in any genetic model in Asians.

Conclusions

This meta-analysis suggests that AURKA rs2273535 polymorphism has an increased risk with BC, especially in Asians. However, rs1047972 polymorphism has a decreased BC risk in Caucasians. Further large scale multicenter epidemiological studies are warranted to confirm this finding.

【 授权许可】

   
2014 Dai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [2]Lo PK, Sukumar S: Epigenomics and breast cancer. Pharmacogenomics 2008, 9:1879-1902.
• [3]Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
• [4]Hemminki K, Granstrom C, Czene K: Attributable risks for familial breast cancer by proband status and morphology: a nationwide epidemiologic study from Sweden. Int. J. Cancer 2002, 100:214-219.
• [5]Carvajal RD, Tse A, Schwartz GK: Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006, 12:6869-6875.
• [6]Castro A, Arlot-Bonnemains Y, Vigneron S, Labbé JC, Prigent C, Lorca T: APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep 2002, 3:457-462.
• [7]Fu J, Bian M, Jiang Q, Zhang C: Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007, 5:1-10.
• [8]Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ: Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003, 9:1420-1426.
• [9]Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S: Aurora-A/STK15/ BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 2004, 25:1631-1639.
• [10]Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M, Takayama T, Naito A, Hirao S, Nakajima Y: Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep 2004, 12:593-599.
• [11]Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR: Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 2002, 62:4115-4122.
• [12]Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S, Balmain A: Identification of Stk6/STK15 as a candidate low-penetrance tumor susceptibility gene in mouse and human. Nat Genet 2003, 34:403-412.
• [13]Ruan Y, Song AP, Wang H, Xie YT, Han JY, Sajdik C, Tian XX, Fang WG: Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population. J Pathol 2011, 225:535-543.
• [14]Shi H, Bevier M, Johansson R, Grzybowska E, Chen B, Eyfjörd JE, Hamann U, Manjer J, Enquist K, Henriksson R, Carlson J, Brandt A, Lascorz J, Butkiewicz D, Pamula-Pilat J, Tecza K, Herms S, Hoffmann P, Hemminki K, Lenner P, Försti A: Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome. Breast Cancer Res Treat 2011, 130:905-916.
• [15]Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women Breast Cancer Res Treat 2010, 120:727-736.
• [16]Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakubowska A, Lubinski J, Gronwald J, Spurdle AB, Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, et al.: AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev 2007, 16:1416-1421.
• [17]Tchatchou S, Wirtenberger M, Hemminki K, Sutter C, Meindl A, Wappenschmidt B, Kiechle M, Bugert P, Schmutzler RK, Bartram CR, Burwinkel B: Aurora kinases A and B and familial breast cancer risk. Cancer Lett 2007, 247:266-272.
• [18]Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE: Breast cancer risk associated with AURKA 91 T > A polymorphism in relation to BRCA mutations. Cancer Lett 2007, 250:206-212.
• [19]Cox DG, Hankinson SE, Hunter DJ: Polymorphisms of the AURKA (STK15/Aurora Kinase) gene and breast cancer risk (United States). Cancer Causes Control 2006, 17:81-83.
• [20]Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker J, Ashworth A, Peto J: Inconsistent associ-ation between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006, 98:1014-1018.
• [21]Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A: Aurora-A/STK15 T91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005, 26:1368-1373.
• [22]Lo YL, Yu JC, Chen ST, Yang HC, Fann CS, Mau YC, Shen CY: Breast cancer risk associated with genotypic polymor-phism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer 2005, 115:276-283.
• [23]Dai Q, Cai QY, Shu XO, Ewart-Toland A, Wen WQ, Balmain A, Gao YT, Zheng W: Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:2065-2070.
• [24]Egan KM, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Kimura MT, Nagase H: STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 2004, 25:2149-2153.
• [25]Sun T, Miao X, Wang J, Tan W, Zhou Y, Yu C, Lin D: Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis 2004, 25:2225-2230.
• [26]Dai ZJ, Wang XJ, Zhao Y, Ma XB, Kang HF, Min WL, Lin S, Yang PT, Liu XX: Effects of interleukin-10 polymorphisms (rs1800896, rs1800871 and rs1800872) on breast cancer risk: evidence from an update meta-analysis. Genet Test Mol Biomarkers 2014, 18:439-445.
• [27]Lukasiewicz KB, Lingle WL: Aurora A, centrosome structure, and the centrosome cycle. Environ Mol Mutagen 2009, 50:602-619.
• [28]Marumoto T, Zhang D, Saya H: Aurora-A - a guardian of poles. Nat Rev Cancer 2005, 5:42-50.
• [29]Qin K, Wu C, Wu X: Two nonsynonymous polymorphisms (F31I and V57I) of the STK15 gene and breast cancer risk: a meta-analysis based on 5966 cases and 7609 controls. J Int Med Res 2013, 41:956-963.